Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review

Stordal, Britta K. ORCID logoORCID: https://orcid.org/0000-0002-7892-951X, Pavlakis, Nick and Davey, Ross A. (2007) Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews, 33 (4) . pp. 347-357. ISSN 0305-7372 [Article] (doi:10.1016/j.ctrv.2007.01.009)

[img] PDF - Final accepted version (with author's formatting)
Restricted to Repository staff and depositor only

Download (268kB) |


Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer. We identified 25 pre-clinical cell models of platinum resistance and 24 clinical trials reporting oxaliplatin based salvage therapy for cisplatin-resistant cancer. The pre-clinical data suggests that there is cross-resistance between cisplatin and oxaliplatin in low-level resistance models. In models with high level resistance (>10-fold) there is less cross-resistance between cisplatin and oxaliplatin, which may be a reason why oxaliplatin is thought to be active in cisplatin-resistant cancer. In clinical trials where oxaliplatin has been used as part of salvage therapy for patients who have failed cisplatin or carboplatin combination chemotherapy, there was a much lower response rate in patients with platinum-refractory or resistant cancers compared to platinum-sensitive cancers. This suggests that there may be cross-resistance between cisplatin and oxaliplatin in the clinic. Oxaliplatin as a single agent had a poor response rate in cisplatin refractory and resistant cancer. Oxaliplatin performed better in combination with other agents for the treatment of platinum-resistant/refractory cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer.

Item Type: Article
Additional Information: Published Online: March 31, 2007
Keywords (uncontrolled): Oxaliplatin, Cisplatin, Resistance, Cross-resistance
Research Areas: A. > School of Science and Technology > Natural Sciences > Biomarkers for Cancer group
Item ID: 14435
Notes on copyright: Full text access restricted pending copyright check.
Useful Links:
Depositing User: Britta Stordal
Date Deposited: 13 Mar 2015 14:02
Last Modified: 25 Jun 2022 03:15
URI: https://eprints.mdx.ac.uk/id/eprint/14435

Actions (login required)

View Item View Item


Activity Overview
6 month trend
6 month trend

Additional statistics are available via IRStats2.